Phase I/II study of two different schedules of pemetrexed (ALIMTA) and erlotinib (TARCEVA) in advanced solid tumors, with emphasis on non-small cell lung cancer (NSCLC)
Phase of Trial: Phase I/II
Latest Information Update: 30 Mar 2010
At a glance
- Drugs Erlotinib (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 22 Jan 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Nov 2006 New trial record.